Regent Investment Management LLC Eli Lilly & CO Transaction History

Regent Investment Management LLC

$373 Million
Q4 2022

A detailed history of Regent Investment Management LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Regent Investment Management LLC holds 4,130 shares of LLY stock, worth $3.74 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

4,130

Previous 4,180 1.2%

Holding current value

$3.74 Million

Previous $1.35 Million 11.76%

% of portfolio

0.4%

Previous 0.39%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	SELL	$321.55 - $374.67 $16,077 - $18,733	-50 Reduced 1.2%	4,130 $1.51 Million
Q2 2022 Jul 15, 2022	SELL	$278.73 - $327.27 $41,809 - $49,090	-150 Reduced 3.46%	4,180 $1.36 Million
Q4 2021 Jan 27, 2022	BUY	$224.85 - $279.04 $33,727 - $41,856	150 Added 3.59%	4,330 $1.2 Million
Q2 2021 Jul 16, 2021	BUY	$180.55 - $233.54 $32,679 - $42,270	181 Added 4.53%	4,180 $960,000
Q2 2020 Jul 29, 2020	SELL	$136.42 - $164.18 $127,416 - $153,344	-934 Reduced 18.93%	3,999 $656,000

Q1 2020 Apr 17, 2020	SELL	$119.05 - $147.35 $35,715 - $44,205	-300 Reduced 5.73%	4,933 $685,000
Q2 2019 Jul 15, 2019	BUY	$110.79 - $129.32 $110,790 - $129,320	1,000 Added 23.62%	5,233 $579,000
Q1 2019 Apr 22, 2019	SELL	$111.31 - $131.02 $15,026 - $17,687	-135 Reduced 3.09%	4,233 $550,000
Q4 2018 Jan 22, 2019	BUY	$105.9 - $118.64 $105,900 - $118,640	1,000 Added 29.69%	4,368 $506,000
Q2 2018 Jul 16, 2018	SELL	$75.7 - $86.88 $7,570 - $8,688	-100 Reduced 2.88%	3,368 $288,000
Q1 2018 Apr 24, 2018	SELL	$74.21 - $87.6 $5,565 - $6,570	-75 Reduced 2.12%	3,468 $269,000
Q3 2017 Oct 12, 2017	BUY	$77.07 - $85.54 $273,059 - $303,068	3,543	3,543 $303,000

Others Institutions Holding LLY

# of Institutions

3,719

Shares Held

738M

Call Options Held

7.09M

Put Options Held

7.24M

View Full List

About ELI LILLY & Co

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $860B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

More about LLY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Regent Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Regent Investment Management LLC with notifications on news.

Account

Regent Investment Management LLC Eli Lilly & CO Transaction History